- Home
- JYD vs CGTX Comparison
JYD vs CGTX Comparison
Compare JYD & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JYD
- CGTX
- Stock Information
- Founded
- JYD 2001
- CGTX 2007
- Country
- JYD China
- CGTX United States
- Employees
- JYD N/A
- CGTX N/A
- Industry
- JYD Oil Refining/Marketing
- CGTX Biotechnology: Pharmaceutical Preparations
- Sector
- JYD Consumer Discretionary
- CGTX Health Care
- Exchange
- JYD Nasdaq
- CGTX Nasdaq
- Market Cap
- JYD 23.3M
- CGTX 20.5M
- IPO Year
- JYD 2023
- CGTX 2021
- Fundamental
- Price
- JYD $0.22
- CGTX $0.32
- Analyst Decision
- JYD
- CGTX Strong Buy
- Analyst Count
- JYD 0
- CGTX 5
- Target Price
- JYD N/A
- CGTX $5.63
- AVG Volume (30 Days)
- JYD 15.2M
- CGTX 1.7M
- Earning Date
- JYD 06-10-2025
- CGTX 05-07-2025
- Dividend Yield
- JYD N/A
- CGTX N/A
- EPS Growth
- JYD N/A
- CGTX N/A
- EPS
- JYD N/A
- CGTX N/A
- Revenue
- JYD $77,444,271.00
- CGTX N/A
- Revenue This Year
- JYD N/A
- CGTX N/A
- Revenue Next Year
- JYD N/A
- CGTX N/A
- P/E Ratio
- JYD N/A
- CGTX N/A
- Revenue Growth
- JYD 13.54
- CGTX N/A
- 52 Week Low
- JYD $0.09
- CGTX $0.22
- 52 Week High
- JYD $8.00
- CGTX $2.54
- Technical
- Relative Strength Index (RSI)
- JYD 34.25
- CGTX 47.90
- Support Level
- JYD $0.21
- CGTX $0.24
- Resistance Level
- JYD $0.24
- CGTX $0.34
- Average True Range (ATR)
- JYD 0.03
- CGTX 0.03
- MACD
- JYD 0.07
- CGTX -0.00
- Stochastic Oscillator
- JYD 4.56
- CGTX 68.84
About JYD Jayud Global Logistics Limited
Jayud Global Logistics Ltd is a end-to-end supply chain solution providers in China, with a focus on providing cross-border logistics services. It offers freight forwarding services, (ii) supply chain management, and (iii) other value-added services.
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.